FDA Adverse Event Malfunction Summary report: N

KYPHX HV-R BONE CEMENT

MDR report key: 1832334 · Received September 3, 2010

Report

Report Number
2953769-2010-00377
Event Type
Malfunction
Date Received
September 3, 2010
Date of Event
January 29, 2010
Report Date
May 14, 2010
Manufacturer
MEDTRONIC SPINE LLC.
Product Code
NDN
PMA / PMN Number
K041584
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
SI
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

REPORT SOURCE: ARTICLE TITLED "ADJACENT VERTEBRAL FRACTURES AFTER PERCUTANEOUS VERTEBRAL AUGMENTATION OF OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURE: A COMPARISON OF BALLOON KYPHOPLASTY AND VERTEBROPLASTY" BY I. MOVRIN, R. VENGUST, R. KOMADINA. THIS ARTICLE DID NOT INDICATE THE BONE CEMENT USED IN THIS STUDY IS KYPHX HV-R BONE CEMENT. DEVICE NOT RETURNED; FOLLOWED-UP WITH AUTHOR.

Description of Event or Problem · 1

IN AN ARTICLE TITLED "ADJACENT VERTEBRAL FRACTURES AFTER PERCUTANEOUS VERTEBRAL AUGMENTATION OF OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURE: A COMPARISON OF BALLOON KYPHOPLASTY AND VERTEBROPLASTY", A PROSPECTIVE STUDY OF 46 PTS (51 VERTEBRAL BODIES) UNDERWENT BALLOON KYPHOPLASTY PROCEDURE AND 27 PTS (32 VERTEBRAL BODIES) UNDERWENT VERTEBROPLASTY PROCEDURE WERE PRESENTED. ALL LEVELS TREATED WERE LOCATED IN THE THORACIC AND LUMBAR SPINE. THE FOLLOWING EVENTS WERE REPORTED: THE 65 CEMENT LEAKAGES WERE REPORTED IN THE BALLOON KYPHOPLASTY GROUP. MOST LEAKAGES WERE PARASPINAL (48%), INTRADISCAL (38%, 1 OUT OF 4 PTS), EPIDURAL (11%), PULMONARY (1.5%), AND FORAMINAL (1.5%). THREE PTS OUT OF 7 CASES IN THE VERTEBROPLASTY GROUP HAD INTRADISCAL CEMENT LEAKAGES. ALL LEAKAGES WERE ASYMPTOMATIC AND THERE WAS NO NEED FOR SURGICAL INTERVENTION. IT WAS NOTED THAT THE BONE CEMENT WAS PREPARED AND INJECTED PER IFU. NO ADDITIONAL INFO WAS REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 KYPHX HV-R BONE CEMENT HIGH VISCOSITY, RADIOPAQUE BONE CEMENT NDN MEDTRONIC SPINE LLC. NA UNK

Patients

Seq Age Sex Outcome Treatment
1 60 YR